{
    "clinical_study": {
        "@rank": "149554", 
        "arm_group": [
            {
                "arm_group_label": "Jaundice infants"
            }, 
            {
                "arm_group_label": "Non-jaundiced infants"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hypothesize that a new BIND (Bilirubin Induced Neurologic Dysfunction)\n      scoring method adapted for the developing world (BIND II, developed by our team for use by\n      health care workers), with additional modifications for community use (the community BIND,\n      C-BIND), will improve the ability to identify infants with ABE and to distinguish ABE from\n      other common causes of neonatal morbidity and mortality compared to currently available\n      survey tools."
        }, 
        "brief_title": "Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Demonstrate BIND II Score of >=5, is Valid for Detecting Moderate to Severe ABE in Neonates <14 Days Old.", 
            "Demonstrate Community-BIND Instrument, a Modified BIND II, is a Valid and Reliable Tool for Detecting ABE.", 
            "Demonstrate That Community-BIND Can be Used for Acquiring Population-based Prevalence of ABE in the Community."
        ], 
        "condition_browse": {
            "mesh_term": "Kernicterus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects will be eligible to participate in the study if all of the following\n             conditions exist:\n\n               1. At time of birth, neonates who are \u2265 35 weeks gestational age or\n\n                  \u2265 2250 grams if gestational age unavailable.\n\n               2. \u2264 14 days old\n\n               3. Parent or guardian has given consent for the infant to participate\n\n        Exclusion Criteria:\n\n          1. Infants with a condition requiring urgent referral to another facility for treatment\n             not available at the hospital study site.\n\n          2. Infants being admitted for a surgical procedure only without an underlying medical\n             illness.\n\n          3. Infants who have a condition that requires no blood draws for treatment of their\n             problem and only reason for blood draw would be study enrollment. -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Days", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Neonates admitted to Massey Street Children's Hospital"
            }
        }, 
        "enrollment": {
            "#text": "626", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754688", 
            "org_study_id": "1109M04335"
        }, 
        "intervention_browse": {
            "mesh_term": "Bilirubin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 18, 2012", 
        "location": {
            "contact": {
                "email": "boolusanya@aol.com", 
                "last_name": "Bolajoka O Olusanya, MBBS", 
                "phone": "011-234-803-334-4300"
            }, 
            "facility": {
                "address": {
                    "city": "Lagos", 
                    "country": "Nigeria"
                }, 
                "name": "Massey Street Children's Hospital"
            }, 
            "investigator": {
                "last_name": "Bolajoko O Olusanya, MBBS", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Nigeria"
        }, 
        "number_of_groups": "2", 
        "official_title": "Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries", 
        "overall_contact": {
            "email": "tslusher@umn.edu", 
            "last_name": "Tina M Slusher, MD", 
            "phone": "612-840-8883"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Tina Slusher, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The orginal BIND was developed in the USA to score infants with Acute Bilirubin Encephalopathy using a focused physical exam (primarily) neuroligic and history to determine the degree of encephalopathy a infant with jaundice displayed.  The BIND has been adapted for Low-Middle-Income Countries. Our plan is to validate it by use a hearing test and physical exam and laboratory exams to rule out other causes of encephalopathy and rule in acute bilirubin encephalopathy", 
            "measure": "Validate the Bilirubin Induced Neurologic Dysfunction II score (BIND II) instrument or scoring tool in a Nigerian hospital", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754688"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "We will translate the BIND II into lay language and they have community workers administer it using pictures and/or short videos along with simple questions to the same infants that the doctors performed the BIND II and who have had a hearing test and compare the score of the community workers with those of the physicians and the results of the hearing test and other labs to validate this score.  The community workers will not exam the infants.  They will do everything through questions and pictures and/or videos.", 
                "measure": "Develop the community Bilirubin Induced Neurologic Dysfunction Score or BIND (C-BIND) score in lay language and validate it in a Nigerian hospital/clinic setting", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "We will take the C-BIND into the community around Massey Street Children's Hospital in year 2 of the study to determine the prevalence of ABE in that community after the C-BIND has been validated as above", 
                "measure": "Conduct a pilot study to determine prevalence of Acute Bilirubin Encephalopathy (ABE) in a Nigerian community using C-BIND.", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2012"
    }
}